The longitudinal trajectories of CA125 identified in this paper may provide more direct information for the prognoses of patients with newly diagnosed, advanced ovarian cancer undergoing first-line chemotherapy treatment after the completion of primary surgery or before interval debulking, and they may be a potential indicator of treatment efficacy. This evidence concerns the gene MUC16 and ovarian cancer.